Interleukin-6: Obstacles to Targeting a Complex Cytokine in Critical Illness

Overview

Journal Lancet Respir Med

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2021 Apr 19

PMID 33872590

Citations 84

Authors

Oliver J McElvaney

Gerard F Curley

Stefan Rose-John

Noel G McElvaney

Affiliations

Soon will be listed here.

Abstract

Circulating concentrations of the pleiotropic cytokine interleukin-6 (IL-6) are known to be increased in pro-inflammatory critical care syndromes, such as sepsis and acute respiratory distress syndrome. Elevations in serum IL-6 concentrations in patients with severe COVID-19 have led to renewed interest in the cytokine as a therapeutic target. However, although the pro-inflammatory properties of IL-6 are widely known, the cytokine also has a series of important physiological and anti-inflammatory functions. An adequate understanding of the complex processes by which IL-6 signalling occurs is crucial for the correct interpretation of IL-6 concentrations in the blood or lung, the use of IL-6 as a critical care biomarker, or the design of effective anti-IL-6 strategies. Here, we outline the role of IL-6 in health and disease, explain the different types of IL-6 signalling and their contribution to the net biological effect of the cytokine, describe the approaches to IL-6 inhibition that are currently available, and discuss implications for the future use of treatments such as tocilizumab in the critical care setting.

Citing Articles

Targeting sepsis through inflammation and oxidative metabolism.

Jacob S, Jacob S, Thoppil J World J Crit Care Med. 2025; 14(1):101499.

PMID: 40060738 PMC: 11671842. DOI: 10.5492/wjccm.v14.i1.101499.

Advances in Interleukin-6 Family Cytokines and the Role in Respiratory Diseases.

Ji T, Huang G, Cao Y, Gao Y, Gao X J Inflamm Res. 2025; 18:3125-3141.

PMID: 40059944 PMC: 11889408. DOI: 10.2147/JIR.S508031.

Laminarin Alleviates Acute Lung Injury Induced by LPS Through Inhibition of M1 Macrophage Polarisation.

Zeng L, Zhang J, Song R, Dong X, Wei Z, Li X J Cell Mol Med. 2025; 29(5):e70440.

PMID: 40045157 PMC: 11882389. DOI: 10.1111/jcmm.70440.

T-2 toxin-induced splenic injury by disrupting the gut microbiota-spleen axis via promoting IL-6/JAK/STAT1 signaling-mediated inflammation and apoptosis and its mitigation by elemental nano-selenium.

Liu M, Li X, Sun H, Yan Y, Xia Z, Refaie A Arch Toxicol. 2025; .

PMID: 40014112 DOI: 10.1007/s00204-025-04005-3.

Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS).

Xiong D, Geng H, Lv X, Wang S, Jia L J Inflamm Res. 2025; 18:2267-2281.

PMID: 39968098 PMC: 11834740. DOI: 10.2147/JIR.S504694.

References

Veiga V, Prats J, Farias D, Rosa R, Dourado L, Zampieri F . Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021; 372:n84. PMC: 7815251. DOI: 10.1136/bmj.n84. View

Matheson N, Wong P, Schuyler M, Travis J . Interaction of human alpha-1-proteinase inhibitor with neutrophil myeloperoxidase. Biochemistry. 1981; 20(2):331-6. DOI: 10.1021/bi00505a016. View

Pierce C, Preston-Hurlburt P, Dai Y, Aschner C, Cheshenko N, Galen B . Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci Transl Med. 2020; 12(564). PMC: 7658796. DOI: 10.1126/scitranslmed.abd5487. View

DORING G . The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med. 1994; 150(6 Pt 2):S114-7. DOI: 10.1164/ajrccm/150.6_Pt_2.S114. View

OShea J, Gadina M, Schreiber R . Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109 Suppl:S121-31. DOI: 10.1016/s0092-8674(02)00701-8. View

Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T . Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A. 1996; 93(1):407-11. PMC: 40247. DOI: 10.1073/pnas.93.1.407. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

10.

Hirota H, Chen J, Betz U, Rajewsky K, Gu Y, ROSS Jr J . Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999; 97(2):189-98. DOI: 10.1016/s0092-8674(00)80729-1. View

11.

Yousif A, Ronsard L, Shah P, Omatsu T, Sangesland M, Moreno T . The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells. Immunity. 2020; 54(2):235-246.e5. PMC: 7836640. DOI: 10.1016/j.immuni.2020.12.001. View

12.

Bergin D, Reeves E, Hurley K, Wolfe R, Jameel R, Fitzgerald S . The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med. 2014; 6(217):217ra1. DOI: 10.1126/scitranslmed.3007116. View

13.

van Vollenhoven R, Fleischmann R, Cohen S, Lee E, Garcia Meijide J, Wagner S . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367(6):508-19. DOI: 10.1056/NEJMoa1112072. View

14.

Brower R, Matthay M, Morris A, Schoenfeld D, Thompson B, Wheeler A . Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342(18):1301-8. DOI: 10.1056/NEJM200005043421801. View

15.

Guerin C, Reignier J, Richard J, Beuret P, Gacouin A, Boulain T . Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013; 368(23):2159-68. DOI: 10.1056/NEJMoa1214103. View

16.

Wiedemann H, Wheeler A, Bernard G, Thompson B, Hayden D, deBoisblanc B . Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006; 354(24):2564-75. DOI: 10.1056/NEJMoa062200. View

17.

Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C . Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic T17 cells. Nat Immunol. 2016; 18(1):74-85. PMC: 5164931. DOI: 10.1038/ni.3632. View

18.

Trayhurn P, Wood I . Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans. 2005; 33(Pt 5):1078-81. DOI: 10.1042/BST0331078. View

19.

Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T . Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A. 1993; 90(21):10193-7. PMC: 47740. DOI: 10.1073/pnas.90.21.10193. View

20.

Heinrich P, Castell J, Andus T . Interleukin-6 and the acute phase response. Biochem J. 1990; 265(3):621-36. PMC: 1133681. DOI: 10.1042/bj2650621. View